Viquidil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 599092

CAS#: 84-55-9

Description: Viquidil is a vasodilator agent.


Price and Availability

Size
Price

Size
Price

Size
Price

Viquidil is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 599092
Name: Viquidil
CAS#: 84-55-9
Chemical Formula: C20H24N2O2
Exact Mass: 324.1838
Molecular Weight: 324.42
Elemental Analysis: C, 74.05; H, 7.46; N, 8.63; O, 9.86


Synonym: Viquidil; LM 192; LM-192; LM-192; Viquidilum;

IUPAC/Chemical Name: 1-(6-methoxyquinolin-4-yl)-3-(3-vinylpiperidin-4-yl)propan-1-one

InChi Key: DKRSEIPLAZTSFD-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H24N2O2/c1-3-14-13-21-10-8-15(14)4-7-20(23)17-9-11-22-19-6-5-16(24-2)12-18(17)19/h3,5-6,9,11-12,14-15,21H,1,4,7-8,10,13H2,2H3

SMILES Code: O=C(C1=CC=NC2=CC=C(OC)C=C12)CCC3C(C=C)CNCC3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Guérémy C, Uzan A, Tamen JC. [Viquidil: study of metabolism using the isotope method. I. Synthesis of 14C-labelled viquidil]. Arzneimittelforschung. 1972 Aug;22(8):1336-40. French. PubMed PMID: 4678396.

2: De Valois JC. Increase in cerebral blood flow in the rabbit by viquidil. Stroke. 1973 Mar-Apr;4(2):218-20. PubMed PMID: 4702310.

3: Hünermann B, Felix R, Wesener K, Winkler C. [Effect of Viquidil on cerebral circulation. Studies using a scintillation camera-computer system]. Arzneimittelforschung. 1973 Aug;23(8):1074-6. German. PubMed PMID: 4801028.

4: Boudouresques J, Gosset A. [Treatment of vascular diseases of the nervous system with Viquidil hydrochloride]. Mars Med. 1972;109(6):453-6. French. PubMed PMID: 4563604.

5: Uzan A, Guérémy C. [Viquidil: study of its metabolism by an isotopic method. 3. Excretion and biotransformation in animals]. Arzneimittelforschung. 1974 Jan;24(1):34-9. French. PubMed PMID: 4406106.

6: Uzan A, Guérémy C. [Viquidil: study of metabolism using the isotope method. II. Absorption and distribution of 14C-labelled viquidil in animals]. Arzneimittelforschung. 1972 Aug;22(8):1341-6. French. PubMed PMID: 4678397.

7: Sim AK, Uzan A. The antithrombotic activity of viquidil, a cerebral vasodilator. Arzneimittelforschung. 1979;29(3):508-11. PubMed PMID: 582736.

8: Cosnier D, Cheucle M, Rispat G, Streichenberger G. Influence of hypercapnia on the cerebrovascular activities of some drugs used in the treatment of cerebral ischemia. Arzneimittelforschung. 1977;27(8):1566-9. PubMed PMID: 578747.

9: Cargnelli G, Finotti P, Melacini P, Ferrari M. [Effects of viquidil on the electric and mechanical activity of smooth muscle]. Boll Soc Ital Biol Sper. 1976 Nov 15;52(21):1808-13. Italian. PubMed PMID: 1037429.

10: Lecrubier C, Uzan A, Samama M. [Effect of a new cerebral vasodilator agent, viquidil, on the aggregation of blood platelets]. Arzneimittelforschung. 1972 Aug;22(8):1334-6. French. PubMed PMID: 4678395.

11: N'Diaye IP, Girard PL, Dumas M. [Trial of a new cerebral vasoregulator: viquidil hydrochloride, in black Africans]. Bull Soc Med Afr Noire Lang Fr. 1974;19(3):257-9. French. PubMed PMID: 4457255.

12: Lebiediewa NW. [Current treatment of cerebrovascular disorder with vasoactive drugs]. Neurol Neurochir Pol. 1981 Jul-Aug;15(4):417-21. Polish. PubMed PMID: 6895779.

13: Nihard P. [Does fluororetinography permit evaluation of the action of drugs: myth or reality?]. Bull Soc Belge Ophtalmol. 1981;192:93-102. French. PubMed PMID: 6896665.

14: Nowicki JP, MacKenzie ET, Spinnewyn B. Effects of agents used in the pharmacotherapy of cerebrovascular disease on the oxygen consumption of isolated cerebral mitochondria. J Cereb Blood Flow Metab. 1982;2(1):33-40. PubMed PMID: 7061602.